Wockhardt Ltd

Type: Company
Name: Wockhardt Ltd
Nationality: India
Fact Sheet: Fact Sheet for Wockhardt Ltd.
First reported 19 hours ago - Updated 19 hours ago - 1 reports

Natco India plant gets Form 483 from FDA

Indian drugmaker Natco has joined a long list of compatriots facing FDA concerns over manufacturing issues. According to The Financial Express , the company received an FDA Form 483 for a finished dosage plant in Telangana after an inspection in May. ... [Published FiercePharmaManufacturing - 19 hours ago]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Equity Report By Ways2Capital 18 Sep 2014

Market regulator Sebi on Thursday censured BSE for accepting an order of 4.55 crore shares in the divestment of government-owned NMDCListFree.org (Press Release) - Thursday, September 18th, 2014NSE WEEKLY NEWS UPDATE✍ Sebi censures BSE for taking late ... [Published ListFree.Org - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

India Must Fix Its Drug Quality Problem

Guest post written by Aparna Mathur and Roger BateMs. Mathur is a resident scholar, and Mr. Bate an adjunct scholar, at the American Enterprise Institute.India’s newly elected Prime Minister Narendra Modi just launched his first official tour of the ... [Published Forbes.com - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program

By a News Reporter-Staff News Editor at Biotech Week Wockhardt Limited announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease ... [Published Pharmacy Choice - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Board of Wockhardt approves scheme of amalgamation

Wockhardt announced that the Board of Directors of the Company at its meeting held on 15 September 2014, inter-alia approved a scheme of Amalgamation for amalgamation/merger of following two wholly owned subsidiaries with the Company:1. Wockhardt Biopharm ... [Published HDFC Securities - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Volumes jump at SKF, Wockhardt counter

Total turnover of SKF India stood at Rs. 53.58 crore and the number of trades were at 1538 on BSE at  2:16PM . SKF is currently trading at Rs. 1,144 and had hit a high of Rs. 1,164 on BSE.Total turnover of Wockhardt Pharma stood at Rs. 40.53 crore and ... [Published India Infoline - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Here are top 10 stocks to keep an eye on Sep 16

- Hero Motocorp, Eicher, Unitech, Infosys, Yes Bank, ZF Steering, Wockhardt, GMR Infra, Tata Motors and Puravankara. ... [Published Moneycontrol.com - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Wockhardt chairman has no plans to sell its business

Habil KhorakiwalaWockhardt chairman Habil Khorakiwala , on Monday, said the company has no intention of selling its business .The statement comes at a point when various news reports had suggested that the company may sell off some of its assets. Some ... [Published DNA India - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 2 reports

Health care companies' scrips canter along

Stocks of Indian pharmaceutical companies seem to be in the pink of health, as investor interest in these has been rising on the back of a weakening currency, the expiry of generic-drug patents later this year and a host of US drug regulatory approvals. ... [Published Business Standard India - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 2 reports

Sensex settles at 2-1/2 week low below 27,000

Trading for the week started on a weak note as key benchmark indices dropped after data showing a muted 0.5% growth in industrial production in July 2014 raised doubts about economic recovery. Key indices extended losses in late trade after remaining ... [Published Business Standard India - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Wockhardt gains ahead of board meeting

Wockhardt rose 1.21% to Rs 863 at 10:19 IST on BSE ahead of the company's board meeting today, 15 September 2014, to consider amalgamation of two wholly-owned subsidiaries with the company.Meanwhile, the BSE Sensex was down 205.26 points, or 0.76%, to ... [Published Business Standard India - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 3 reports

Wockhardt appoints Manas Datta as CFO

Mumbai-based generic drugmaker Wockhardt Ltd has appointed Manas Datta as its chief financial officer (CFO), as per a stock market disclosure.Datta takes over from Giri Giridhar, who moved to Merck & Co, as a senior director (finance) and board member ... [Published VC Circle - Sep 12 2014]

Quotes

The team of two neurosurgeons Dr Chandrashekhar Pakhmode and Dr Pramod Giri, who run a hospital named 'Neuron', began using the "frameless stereostatic guidance system about 7-8 months back. They have operated on 35 patients using this new bioengineering tool. Another team of Dr Sameer Paltewar and Dr Nilesh Agrawal at Meditrina hospital used the navigation system to remove a huge blood mass (haematoma) caused due to sudden bleeding in the brain of a 60-year-old man from Balaghat last Friday."
...It said the 6 observations had to do with lack of control processes, including procedures to make sure drugs hit the "strength, quality and purity they purport or are represented to have." Plants operated by other large Indian drugmakers like Ranbaxy Laboratories , Wockhardt and Sun Pharmaceuticals , as well as the Canadian drug maker Apotex...
"I think there is a lot of consolidation and event driven triggers that will panpan out going forward. I am not saying this because Sun Pharmaceutical Industries and Lupin have signed a deal with Merck but more importantly I think now is the time to separate men from the boys. So, while I am negative on a Sun Pharma which I think still has an FDA import alert looming over its Halol plant where things seem to have died down for the time being. Equally I think despite the heady and gravity defined run that Lupin has seen, if you are talking of a Rs 69 earnings per share (EPS) which is what I expect them to do in FY16, at shy of Rs 1400 this stock is available just about 20 times which is still a discount to some of these sector biggies" she said
In this regard, Dr. Habil Khorakiwala, Wockhardt Founder & Chairman said "Globally there is a significant antibiotic vacuum due to dual impact of rise in new resistant pathogens and declining research in this area which causes over 50,000 deaths in USA and Europe combined despite having excellent healthcare services. The emerging world may as well be sitting on an antibiotic time-bomb ready to explode. Superficially the bacterial diseases can be divided in two categories, gram positive and gram negative and these pathogens have prevalence in both of them. Over the years Wockhardt has developed a strong anti-infective program which focuses on development of drugs which target this antibiotic gap in both gram positive and gram negative domains. These two drugs act against one of the globally rising class of pathogens MRSA (Methicillin-resistant Staphylococcus Aureus) which causes a range of diseases from the skin infection to severe respiratory infections. In case of severe infections like Hospital Acquired Pneumonia (HAP) current medical cure has a very limited reach causing a high unmet need and mortality. Both of these drugs are effective against MRSA and have shown potential in treatment of HAP. WCK 771 is an intravenous (IV) drug while WCK 2349 is a solid oral tablet, which is a significant positive for the drug development scenario as currently there is very little advance drug research in developing solid oral dosages. Most of the research is in developing intravenous drugs which requires significantly higher medical attention and increased rate of hospitalization wherein the chances of catching other infections is very high."

More Content

All (289) | News (275) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (3) | Press Releases (0)
sort by: Date | Relevance
Now comps guide surgeons through brain during s... [Published Times of India - 12 hours ago]
Natco India plant gets Form 483 from FDA [Published FiercePharmaManufacturing - 19 hours ago]
Equity Report By Ways2Capital 18 Sep 2014 [Published ListFree.Org - Sep 18 2014]
Prefer pharma, Tata Steel, Ambuja Cements: Sanj... [Published Moneycontrol.com - Sep 18 2014]
Sensex up over 300 pts as bulls call the shots [Published Sify - Sep 18 2014]
India Must Fix Its Drug Quality Problem [Published Forbes.com - Sep 17 2014]
U.S. FDA Grants QIDP Status for Wockhardt Anti-... [Published Pharmacy Choice - Sep 17 2014]
Volumes jump at SKF, Wockhardt counter [Published India Infoline - Sep 17 2014]
Daily Market Strategy - What correction! A bett... [Published India Infoline - Sep 17 2014]
Board of Wockhardt approves scheme of amalgamation [Published HDFC Securities - Sep 17 2014]
Ten cases where foreign M&As have destroyed wealth [Published Economic Times - Sep 17 2014]
India’s drug industry to touch $48 billion by 2018 [Published India Brand Equity Foundation - Sep 16 2014]
Peace awards for Dalai Lama, Malala announced i... [Published Times of India - Sep 16 2014]
Indias fast power [Published IISS - Sep 16 2014]
Wockhardt stock tumbles 8% [Published India Infoline - Sep 16 2014]
India Insulin Market Review to 2018 - Intensify... [Published Scoop Asia - Sep 16 2014]
Future outlook and projections of the insulin m... [Published Scoop Asia - Sep 16 2014]
Here are top 10 stocks to keep an eye on Sep 16 [Published Moneycontrol.com - Sep 16 2014]
Wockhardt chairman has no plans to sell its bus... [Published DNA India - Sep 16 2014]
Health care companies' scrips canter along [Published Business Standard India - Sep 15 2014]
Sensex settles at 2-1/2 week low below 27,000 [Published Business Standard India - Sep 15 2014]
Weaker currency, patent expiration boost for he... [Published Business Standard India - Sep 15 2014]
PSU bank stocks gain [Published Business Standard India - Sep 15 2014]
Data Integrity Key to GMP Compliance [Published PharmTech.com - Sep 15 2014]
Wockhardt gains ahead of board meeting [Published Business Standard India - Sep 15 2014]
‘Aadhaar secure, ensures privacy’ [Published The Hindu - Sep 12 2014]
Sun Pharma: Is the Street's nervousness justified? [Published Business Standard India - Sep 12 2014]
BSE Mid- & Small-cap scrips close marginally up [Published India Infoline - Sep 12 2014]
Wockhardt appoints Manas Datta as CFO [Published VC Circle - Sep 12 2014]
Manas Datta appointed Wockhardt CFO [Published Hindu Business Line - Sep 12 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA grants QIDP status for Wockhardt anti-infec... [Published PBR - News - Sep 01 2014]
Wockhardt Limited has announced a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration ...
U.S. FDA Grants QIDP Status for Wockhardt Anti-... [Published PR Newswire: Health - Sep 01 2014]
PARSIPPANY, N.J., Aug. 31, 2014 /PRNewswire/ -- Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease ...
CEFTRIAXONE Injection, Powder, For Solution CEF... [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Updated Date: Aug 19, 2014 EST ...
BDA Named M&A Advisor of the Year at the 2014 A... [Published PR.com Press Releases - Jun 21 2014]
New York, NY, June 21, 2014 --( PR.com )-- Business Development Asia LLC (“BDA”) was named M&A Advisor of the Year at the ACG Champion’s Awards, held on June 19th in New York. ACG New York is the leading association for middle market dealmaking professionals: ...
What Did the FDA Find at the Wockhardt Plant? L... [Published WSJ.com: India Real Time - Jun 04 2014]
A recent FDA inspection of a key U.S. plant run by Wockhardt, an Indian drug maker that is a large supplier to the U.S., found a dozen quality-control problems and is likely to further underscore regulatory concerns about the Indian pharmaceutical industry's ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.